Evidence map›Paper›PMID 17956607›Full record

ArticleBMC structural biology2007

The structure of Mycobacteria 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery.

Lori Buetow, Amanda C Brown, Tanya Parish, William N Hunter

Abstract readComparative Study
In one paragraph

Article in BMC structural biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Metabolite Dysregulation by Pranlukast inMolecules (Basel, Switzerland) · 2022
    Article
  2. Article
  3. Review
  4. Crystal structure of IspF fromBioscience reports · 2018
    Article
  5. Review
  6. Article
  7. Metallobiology of Tuberculosis.Microbiology spectrum · 2014
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Biochemistry of the non-mevalonate isoprenoid pathway.Cellular and molecular life sciences : CMLS · 2011
    Review
  14. Article
  15. Article
  16. Article
  17. A triclinic crystal form of Escherichia coli 4-diphosphocytidyl-2C-methyl-D-erythritol kinase and reassessment of the quaternary structure.Acta crystallographica. Section F, Structural biology and crystallization communications · 2010
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lori BuetowDivision of Biological Chemistry and Molecular Microbiology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK. l.buetow@dundee.ac.uk
Amanda C Brown
Tanya Parish
William N Hunter

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThe prevalence of tuberculosis, the prolonged and expensive treatment that this disease requires and an increase in drug resistance indicate an urgent need for new treatments. The 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid precursor biosynthesis is an attractive chemotherapeutic target because it occurs in many pathogens, including Mycobacterium tuberculosis, and is absent from humans. To underpin future drug development it is important to assess which enzymes in this biosynthetic pathway are essential in the actual pathogens and to characterize them.

resultsThe fifth enzyme of this pathway, encoded by ispF, is 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF). A two-step recombination strategy was used to construct ispF deletion mutants in M. tuberculosis but only wild-type double crossover strains were isolated. The chromosomal copy could be deleted when a second functional copy was provided on an integrating plasmid, demonstrating that ispF is an essential gene under the conditions tested thereby confirming its potential as a drug target. We attempted structure determination of the M. tuberculosis enzyme (MtIspF), but failed to obtain crystals. We instead analyzed the orthologue M. smegmatis IspF (MsIspF), sharing 73% amino acid sequence identity, at 2.2 A resolution. The high level of sequence conservation is particularly pronounced in and around the active site. MsIspF is a trimer with a hydrophobic cavity at its center that contains density consistent with diphosphate-containing isoprenoids. The active site, created by two subunits, comprises a rigid CDP-Zn2+ binding pocket with a flexible loop to position the 2C-methyl-D-erythritol moiety of substrate. Sequence-structure comparisons indicate that the active site and interactions with ligands are highly conserved.

conclusionOur study genetically validates MtIspF as a therapeutic target and provides a model system for structure-based ligand design.

Indexed as

Drug DesignAmino Acid SequenceBacterial ProteinsBinding SitesCloning, MolecularConserved SequenceCrystallography, X-RayDNA, BacterialElectroporationGene DeletionGene ExpressionGenes, BacterialHydrogen BondingHydrophobic and Hydrophilic InteractionsLigandsMagnesiumBacterial ProteinsDNA, BacterialLigandsMagnesiumProtein SubunitsWaterZinc

Identifiers

PMID17956607
PMCPMC2151065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.